2025-04-18 - Analysis Report
## Equinix Inc. (EQIX) Stock Report

**0. Summary of Key Figures:**

* **Cumulative Return (EQIX):** 80.48%
* **Cumulative Return (VOO/S&P 500):** 76.18%
* **Return Difference (EQIX - VOO):** 4.3%
* **Relative Divergence:** 36.8% (Indicates EQIX outperformed VOO relative to its historical performance range)
* **Current Price:** $790.15
* **Expected Long-Term Return (vs. S&P 500):** 12%

**1. Company Overview and Performance Comparison:**

Equinix Inc. is a global interconnection and data center company.  Over the period analyzed, EQIX significantly outperformed the S&P 500 (VOO), with a cumulative return 4.3 percentage points higher.  While this difference is positive, the relative divergence of 36.8% suggests that this outperformance is within the typical historical range of relative performance and not exceptionally high compared to past periods. The provided Alpha and Beta analysis shows fluctuating performance relative to the market (Beta) and periods of outperformance (positive Alpha). The market capitalization has grown significantly over the observed period.


| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 48.0% | 53.7% | 15.0% | 0.0 | 38.7 |
| 2016-2018  | -12.0% | 64.1% | -33.0% | -0.0 | 30.8 |
| 2017-2019  | 37.0% | 64.1% | 3.0% | 0.7 | 52.0 |
| 2018-2020  | 40.0% | 64.1% | 9.0% | 0.4 | 64.6 |
| 2019-2021  | 90.0% | 63.4% | 29.0% | 0.3 | 77.7 |
| 2020-2022  | 7.0% | 68.4% | -2.0% | 0.3 | 61.2 |
| 2021-2023  | -3.0% | 68.4% | -23.0% | 0.8 | 76.8 |
| 2022-2024  | 31.0% | 70.7% | 11.0% | 0.9 | 91.8 |
| 2023-2025  | -6.0% | 71.5% | 0.6 | 0.6 | 77.3 |


**2. Recent Price Movement:**

* **Closing Price:** $790.15
* **5-Day Moving Average:** $783.40
* **20-Day Moving Average:** $799.61
* **60-Day Moving Average:** $866.41

The price is currently below its 20-day and 60-day moving averages, suggesting a potential short-term downtrend.  The recent price increase of $1.47 (from the previous close) is modest and doesn't signal a dramatic price swing.

**3. Technical Indicators and Expected Return:**

* **Market Risk Indicator (MRI):** 0.42 (Low to Medium Risk)
* **RSI:** 47.34 (Slightly below neutral; not oversold)
* **PPO:** 0.33 (Positive, suggesting upward momentum)
* **Recent Relative Divergence Change:** +4.3 (Short-term upward trend)
* **Expected Return:** 12% (over S&P 500 for long-term, 2+ years, investments)

The indicators suggest a relatively neutral to slightly positive outlook. The MRI suggests a manageable level of risk. The relatively small price change doesn't indicate a significant shift. The expected return shows considerable potential for outperformance.

**4. Recent Earnings Analysis:**

| Date       | EPS   | Revenue    |
|------------|-------|------------|
| 2024-10-30 | 3.11  | $2.20 B    |
| 2024-08-07 | 3.17  | $2.16 B    |
| 2024-05-08 | 2.44  | $2.13 B    |
| 2023-10-27 | 2.94  | $2.06 B    |
| 2024-10-30 | 2.94  | $2.06 B    | *(Duplicate Entry - Potential Data Error)*


Earnings have been relatively stable, with some fluctuations.  There's a potential data duplication issue (2 entries for 2024-10-30). Further investigation into data accuracy is necessary.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue  | Profit Margin |
|---------|----------|---------------|
| 2024-12-31 | $2.26B  | 47.10%       |
| 2024-09-30 | $2.20B  | 50.11%       |
| 2024-06-30 | $2.16B  | 49.88%       |
| 2024-03-31 | $2.13B  | 48.71%       |
| 2023-12-31 | $2.11B  | 48.27%       |

Revenue is steadily increasing, and profit margins remain consistently high, indicating strong financial health.


**Capital and Profitability:**

| Quarter | Equity    | ROE     |
|---------|-----------|---------|
| 2024-12-31 | $13.53B  | -0.10%  |
| 2024-09-30 | $13.59B  | 2.19%   |
| 2024-06-30 | $12.28B  | 2.45%   |
| 2024-03-31 | $12.30B  | 1.88%   |
| 2023-12-31 | $12.49B  | 1.82%   |

Equity shows some fluctuation, and ROE is generally positive but shows variability.  The negative ROE in Q4 2024 requires further investigation.


**6. Overall Analysis:**

EQIX has shown consistent outperformance against the S&P 500, but the magnitude of this outperformance is within its historical range.  Financial statements indicate a healthy company with growing revenue and generally high profit margins.  However, some data inconsistencies (duplicate earnings entry, fluctuating ROE) require further clarification.  The technical indicators suggest a neutral to positive outlook, although the price is currently below its moving averages. The projected long-term return remains promising, suggesting potential for continued outperformance, provided that the underlying business fundamentals remain strong and the data inconsistencies are resolved.  Further due diligence is recommended before making any investment decisions.
